Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Mimedx Group Inc (NASDAQ: MDXG) closed the day trading at $6.32 down -8.14% from the previous closing price of $6.88. In other words, the price has decreased by -$8.14 from its previous closing price. On the day, 1.51 million shares were traded. MDXG stock price reached its highest trading level at $6.68 during the session, while it also had its lowest trading level at $6.175.
Ratios:
For a better understanding of MDXG, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.44. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 02, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.
On March 07, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12.
On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.Craig Hallum initiated its Buy rating on October 27, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Maersk-Moller Kimberly sold 1,759 shares for $8.04 per share. The transaction valued at 14,142 led to the insider holds 309,077 shares of the business.
Hulse William Frank IV sold 54,596 shares of MDXG for $430,762 on Mar 13 ’25. The General Counsel and CAO now owns 440,178 shares after completing the transaction at $7.89 per share. On Mar 13 ’25, another insider, Maersk-Moller Kimberly, who serves as the Chief Commercial Officer of the company, sold 4,106 shares for $7.89 each. As a result, the insider received 32,396 and left with 310,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 931353152 and an Enterprise Value of 845704512. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.21, and their Forward P/E ratio for the next fiscal year is 18.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 4.81. Its current Enterprise Value per Revenue stands at 2.4 whereas that against EBITDA is 13.465.
Stock Price History:
The Beta on a monthly basis for MDXG is 1.85, which has changed by -0.14246947 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, MDXG has reached a high of $10.14, while it has fallen to a 52-week low of $5.47. The 50-Day Moving Average of the stock is -15.70%, while the 200-Day Moving Average is calculated to be -16.11%.
Shares Statistics:
Over the past 3-months, MDXG traded about 551.31K shares per day on average, while over the past 10 days, MDXG traded about 569520 shares per day. A total of 146.93M shares are outstanding, with a floating share count of 115.91M. Insiders hold about 21.34% of the company’s shares, while institutions hold 49.68% stake in the company. Shares short for MDXG as of 1744675200 were 4835160 with a Short Ratio of 8.77, compared to 1741910400 on 4150863. Therefore, it implies a Short% of Shares Outstanding of 4835160 and a Short% of Float of 4.099999700000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Mimedx Group Inc (MDXG) is currently drawing attention from 2.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.06, with high estimates of $0.07 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.28 and $0.26 for the fiscal current year, implying an average EPS of $0.27. EPS for the following year is $0.34, with 2.0 analysts recommending between $0.38 and $0.3.
Revenue Estimates
3 analysts predict $90.39M in revenue for the current quarter. It ranges from a high estimate of $91.4M to a low estimate of $89.28M. As of the current estimate, Mimedx Group Inc’s year-ago sales were $87.21MFor the next quarter, 3 analysts are estimating revenue of $93.46M. There is a high estimate of $94.78M for the next quarter, whereas the lowest estimate is $91.6M.
A total of 5 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $375M, while the lowest revenue estimate was $374M, resulting in an average revenue estimate of $374.48M. In the same quarter a year ago, actual revenue was $348.88MBased on 5 analysts’ estimates, the company’s revenue will be $417.3M in the next fiscal year. The high estimate is $430M and the low estimate is $407M.
